Avocates et Avocats Simon Olstein
Simon Olstein

Simon Olstein

Senior Associate
MLaw, Avocat

Icon Vcard vCard

Site

Bâle

Contact

Téléphone direct: +41 58 658 14 15
simon.olstein@walderwyss.com

Curriculum vitae

Télécharger le PDF

Domaines d'activité: Corporate / M&A Santé et sciences de la vie

Simon Olstein is a Senior Associate at Walder Wyss. He advises clients predominantly in the healthcare and life sciences sector, with a particular focus on contract and corporate law, M&A transactions, and venture capital and financing. In this capacity, he advises pharmaceutical, biotech and medtech companies and private equity and venture capital investors on domestic and cross-border M&A, financings and corporate matters.

His practice covers the full range of life sciences agreements, including license, collaboration, manufacture, research and development, clinical trial, supply and distribution agreements. He also has broad experience in transactional work, including due diligence, and advises on Swiss corporate and healthcare regulatory matters.

Born in 1993, Simon Olstein studied law at the University of Basel (MLaw 2018) and at Tel Aviv University and passed the bar exam in the Canton of Basel-Stadt in 2021. Prior to joining Walder Wyss, he gained professional experience at the Civil Court of Basel-Stadt and at a commercial law firm in Zurich, among others.

In addition, Simon Olstein worked in the legal department of a leading global life sciences company at its divisional headquarters in Basel and, before joining Walder Wyss, most recently served as Legal Counsel for an international specialty pharmaceutical company. In 2023, he completed a Certificate of Advanced Studies (CAS) in Finance and Accounting for Lawyers at the Lucerne University of Applied Sciences and Arts (HSLU).

Simon Olstein primarily advises clients in German and English and speaks French as well. He is admitted to practice throughout Switzerland.

Swiss MedTech company Distalmotion SA closes USD 150m Series G Financing Round

dsm-firmenich sells Pentapharm

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics

TransPerfect Acquires Apostroph Group

Walder Wyss advised Novo Holdings on the acquisition of Catalent

KARL STORZ acquires Anklin

Promotions Senior Associates

Lithography von Beyond Gravity wird Teil von ZEISS

SixPeaks Bio AG debuts with USD 110 million in Funding

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

CONVOTIS stärkt seine Position in der Schweiz durch die neueste Akquisition der acdalis AG, einem anerkannten Spezialisten für Managed Cloud und Infrastruktur Services.

Zusammenschluss von SETEX und Datatex mit Elvaston

CONVOTIS startet mit der Übernahme der JMC Gruppe als Plattformunternehmen in den Schweizer IT Markt und stärkt seine Positionierung im Segment der Managed Services und digitalen Plattformlösungen.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Pierre Fabre Laboratories acquires Vertical Bio AG

Das Familienunternehmen Henke-Sass, Wolf GmbH übernimmt die Zünd Präzisionsoptik AG

Skribble AG completes Series A round of funding

groupe.id joins Elvaston
Autres Actualités

Procurement options for medical devices in the light of an impending supply gap in Switzerland

| par Alexander Gutmans, Simon Olstein, Dennis Zingg et Frederik Weber | dans: «MedizinProdukteRecht (MPR)» 5/2022 | 165-176 | Zeitschriften

Autres avocats

S’abonner à la newsletter